Teamwork Financial Advisors LLC Has $244,000 Stock Position in Novo Nordisk A/S $NVO

Key Points

• Teamwork Financial Advisors sharply reduced its Novo Nordisk position by 94.9% in the second quarter, selling 95,033 shares and retaining 5,091 shares valued at approximately $244,000.
• Analyst sentiment is largely cautious: 14 analysts rate NVO a Hold, four rate it Buy and one rates it Sell. The consensus rating is Hold, with an average price target of $64.94.
• Novo Nordisk shares opened at $45.15, down 3.1%, amid concerns about competition and future growth. Positive developments include encouraging pediatric Wegovy trial results and a planned DKK 15 billion share-buyback program, while halted cardiovascular trials highlight diversification risks.

Teamwork Financial Advisors LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 94.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,091 shares of the company's stock after selling 95,033 shares during the quarter. Teamwork Financial Advisors LLC's holdings in Novo Nordisk A/S were worth $244,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Revolve Wealth Partners LLC boosted its stake in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after buying an additional 200 shares during the last quarter. CoreCap Advisors LLC increased its position in shares of Novo Nordisk A/S by 4.7% in the second quarter. CoreCap Advisors LLC now owns 5,341 shares of the company's stock valued at $256,000 after acquiring an additional 242 shares during the last quarter. Carson Advisory Inc. increased its position in shares of Novo Nordisk A/S by 2.2% in the first quarter. Carson Advisory Inc. now owns 12,316 shares of the company's stock valued at $453,000 after acquiring an additional 268 shares during the last quarter. Bradley Foster & Sargent Inc. CT raised its holdings in Novo Nordisk A/S by 0.6% during the first quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company's stock worth $1,726,000 after acquiring an additional 272 shares in the last quarter. Finally, Arlington Partners LLC raised its holdings in Novo Nordisk A/S by 4.4% during the second quarter. Arlington Partners LLC now owns 6,777 shares of the company's stock worth $325,000 after acquiring an additional 283 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a "hold" rating to a "sell" rating in a research note on Thursday, August 27th. Finally, BMO Capital Markets reaffirmed a "market perform" rating and issued a $47.00 target price on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Four investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $64.94.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy succeeds in pediatric obesity trial: In the Phase 3 STEP Young study, 40.4% of children ages 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with 0% in the placebo group. The trial met its primary endpoint, with no new safety concerns reported involving growth or puberty. The results could support a future label expansion and open a significant new market for Wegovy. Novo Nordisk reports positive semaglutide trial results in young children
• Positive Sentiment: Share repurchases provide support: Novo is continuing a broader share-buyback program of up to DKK 15 billion over 12 months, which may support earnings per share and signal management’s confidence in the company’s valuation. Novo Nordisk share repurchase programme
• Neutral Sentiment: Valuation is attracting investor interest: Novo Nordisk trades substantially below its 2024 high and at a relatively modest earnings multiple, but investors remain focused on whether growth can reaccelerate amid intensifying competition from Eli Lilly and uncertainty surrounding the next generation of obesity medicines. Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
• Negative Sentiment: Two cardiovascular trials were halted: Novo discontinued two Phase 3 trials of experimental IL-6 drug ziltivekimab after disappointing results, weakening its diversification strategy and reinforcing concerns that the company is overly dependent on Ozempic, Wegovy and related products. Novo scraps two more heart drug trials
• Negative Sentiment: Management remains cautious on the peptide boom: The new CEO has warned that enthusiasm for peptide-based therapies may be excessive, adding to concerns about competition, pricing and the durability of the obesity-drug growth cycle. Why the CEO of Wegovy maker Novo Nordisk isn't yet sold on the peptide craze

Novo Nordisk A/S Stock Down 3.1%

NVO stock opened at $45.15 on Wednesday. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The business's 50 day simple moving average is $47.84 and its 200 day simple moving average is $43.71. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $201.60 billion, a PE ratio of 11.04, a PEG ratio of 1.56 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The business had revenue of $11.98 billion during the quarter. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.45 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were paid a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 19.80%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.